InSilico Medicine has raised $10 million from six investors, according to a filing with the Securities and Exchange Commission.

InSilico is in the business of collecting and analyzing genetic codes to make drug discoveries for aging and age-related diseases. The company uses advances in molecular biology and big data analysis with computer modeling and simulation.

The bioinformatics company has reported revenues of less than $1 million. The company is located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore.

The date of the first sale occurred on Dec. 10, and each investor contributed at least $25,000.

InSilico pursues internal drug programs in cancer, Parkinson’s, Alzheimer’s and sarcopenia (loss of muscle tissue due to aging) and provides services to pharmaceutical and cosmetics companies.

On Feb. 3 the company announced that it started a research project with one of the world’s largest research and medical networks, South Korea-based Gachon University and Gil Medical Center.

The intent of the long-term collaboration is to develop artificially intelligent markers of aging and health status as well as interventions intended to slow down or even reverse the processes leading to the age-related loss of function.

Aging research is a controversial area because of failed claims and promises made by companies in the business of anti-aging.

“Our mission is to extend healthy human longevity,” said Alex Zhavoronkov, chief executive officer of InSilico, in a Jan. 11 press release. “With over 20 academic publications published in 2015 and over 150 collaborators worldwide, we are very excited to present our results that will lead to faster and more effective diagnostics and cures in many age-related diseases,”

A brief company video can be found here.